Spyre Therapeutics, Inc.

SYRE

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001636282

SEC filings (opens in a new tab)

In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Spyre Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023 All holders in Q2 2023

13F holders of SYRE: Q2 2023 compared with Q3 2023
Measure	Q2 2023	Q3 2023	Change
Holders	44	29	−15
SharesConverted for a 1-for-25 split	2.84M	3.58M	+740.7K (+26.1%)
Value	$31.9M	$43.9M	+$11.9M (+37.4%)

New holders (3)

Institutions that held Spyre Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to SYRE in Q3 2023
Institution	Shares	Value	% of portfolio
Polar Capital Holdings Plc	300,000	$3.67M	0.03%
Citadel Advisors LLC	97,053	$1.19M	0.00%
Perceptive Advisors LLC	81,116	$993.7K	0.03%

Sold out (18)

Institutions that held Spyre Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of SYRE in Q3 2023
Institution	Shares, Q2 2023	Value, Q2 2023
Nantahala Capital Management, LLC	4,101,193	$1.85M
Baker Bros. Advisors LP	3,410,106	$1.54M
Samsara BioCapital, LLC	883,720	$398.1K
Goldman Sachs Group Inc	558,650	$251.7K
University of Texas/Texas Am Investment Managment Co	245,678	$111.0K
Carlyle Group Inc.	240,500	$108.2K
State Street Corp	195,089	$87.9K
HRT Financial LP	164,528	$74.0K
Northern Trust Corp	97,927	$44.1K
Jane Street Group, LLC	54,278	$24.5K
Susquehanna International Group, LLP	36,179	$16.3K
Franklin Resources Inc	31,364	$14.1K
Bank of New York Mellon Corp	23,233	$10.5K
UBS Group AG	8,091	$3.65K
Simplex Trading, LLC	2,800	$1.00K
Group One Trading, L.P.	572	$258
Barclays PLC	99	$45
BNP Paribas Arbitrage, SA	1	$0